Generic Name and Formulations:
Nitroglycerin 2% (15mg/inch); oint; contains lanolin.
Indications for NITRO-BID:
Prophylaxis of angina. Not for acute attacks.
Apply, using applicator, usually to the chest and occlude. Initially ½ inch on awakening and then 6 hrs later; may increase to 1 inch, then to 2 inches twice daily.
Acute MI. CHF. Hypotension. Volume depleted. Hypertrophic cardiomyopathy. Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Vasodilating effects potentiated with alcohol, other vasodilators. Orthostatic hypotension with calcium channel blockers.
Headache, dizziness, flushing, orthostatic hypotension, rash; syncope, methemoglobinemia (rare).
Oint—30g, 60g (w. applicator); Oint—48 x 1g packets
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|